Vasopressin and octreotide are used in the management of severe cases of which condition?

• A. Esophageal variceal bleeding
• B. Crohn disease
• C. Peptic ulcer disease
• D. Acute pancreatitis

Answer: (A)

When bleeding is coming from esophageal varices due to portal hypertension, the immediate goal is to rapidly reduce portal venous inflow to lower the pressure driving the variceal bleed. Vasopressin and octreotide are used for this purpose because they shrink the splanchnic circulation, which directly decreases blood flow into the portal system.

Vasopressin acts by constricting splanchnic vessels via the V1 receptor, cutting down portal venous inflow. Octreotide, a somatostatin analogue, also reduces splanchnic blood flow and thus portal pressure, but with a lower risk of systemic ischemia. These drugs are typically used as temporizing therapy in severe variceal hemorrhage to stabilize the patient and facilitate definitive control with endoscopic treatment.

They’re not standard therapy for Crohn disease, peptic ulcer disease, or acute pancreatitis, where management focuses on anti-inflammatory or antimicrobial therapy, endoscopic hemostasis for non-variceal bleeds, acid suppression, or supportive care rather than targeted reduction of portal venous pressure.